Enhancement of Natural Killer Cell Cytotoxicity by Sodium/Iodide Symporter Gene-Mediated Radioiodine Pretreatment in Breast Cancer Cells

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Kim, Hae Won ^a,b   Kim, Jung Eun ^a   Hwang, Mi Hye ^a   Jeon, Yong Hyun ^a   Lee, Sang Woo ^a   Lee, Jaetae ^a   Zeon, Seok Kil ^b   Ahn, Byeong Cheol ^a  

^a Kyungpook National University School of Medicine   (South Korea)

^b Keimyung University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH RECEPTOR 5; FAS ANTIGEN; IODINE 131; SODIUM IODIDE SYMPORTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER RADIOTHERAPY; CELL DEATH; CELL THERAPY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PHENOTYPE; RADIOIODINE THERAPY; RADIOTHERAPY; RECURRENT CANCER; THERAPY EFFECT; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; UPREGULATION;

ANIMALS; BREAST NEOPLASMS; CELL LINE; FEMALE; HUMANS; IODINE RADIOISOTOPES; KILLER CELLS, NATURAL; MICE; MICE, INBRED BALB C; MICE, NUDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SYMPORTERS;

EID: 84881119667     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070194     Document Type: Article

References (37)

1. DeSantis C, Siegel R, Bandi P, Jemal A, (2011) Breast cancer statistics, 2011. CA Cancer J Clin 61: 409-418.
2. Ugnat AM, Xie L, Morriss J, Semenciw R, Mao Y, (2004) Survival of women with breast cancer in Ottawa, Canada: variation with age, stage, histology, grade and treatment. Br J Cancer 90: 1138-1143.
3. Nieto Y, (2003) The verdict is not in yet. Analysis of the randomized trials of high-dose chemotherapy for breast cancer. Haematologica 88: 201-211.
4. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, et al. (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13: 4429-4434.
5. Dewan MZ, Terunuma H, Takada M, Tanaka Y, Abe H, et al. (2007) Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo. Breast Cancer Res Treat 104: 267-275.
6. Sutlu T, Alici E, (2009) Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J Intern Med 266: 154-181.
7. Castriconi R, Dondero A, Cilli M, Ognio E, Pezzolo A, et al. (2007) Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/scid mice. Cancer Immunol Immunother 56: 1733-1742.
8. Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, et al. (2011) A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 13: 98-107.
9. Kruschinski A, Moosmann A, Poschke I, Norell H, Chmielewski M, et al. (2008) Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci U S A 105: 17481-17486.
10. Ames E, Hallett WH, Murphy WJ, (2009) Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition. Clin Exp Immunol 155: 504-513.
11. Ahn BC, (2012) Sodium iodide symporter for nuclear molecular imaging and gene therapy: from bedside to bench and back. Theranostics 2: 392-402.
12. Nowosielska EM, Cheda A, Wrembel-Wargocka J, Janiak MK, (2011) Anti-neoplastic and immunostimulatory effects of low-dose X-ray fractions in mice. Int J Radiat Biol 87: 202-212.
13. Ishikawa E, Tsuboi K, Saijo K, Takano S, Ohno T, (2004) X-irradiation to human malignant glioma cells enhances the cytotoxicity of autologous killer lymphocytes under specific conditions. Int J Radiat Oncol Biol Phys 59: 1505-1512.
14. Schmidt J, Patrut EM, Ma J, Jager D, Knaebel HP, et al. (2006) Immunomodulatory impact of interferon-alpha in combination with chemoradiation of pancreatic adenocarcinoma (CapRI). Cancer Immunol Immunother 55: 1396-1405.
15. Jeon YH, Choi Y, Kim CW, Kim YH, Youn H, et al. (2010) Human sodium/iodide symporter-mediated radioiodine gene therapy enhances the killing activities of CTLs in a mouse tumor model. Mol Cancer Ther 9: 126-133.
16. Hori T, Kondo T, Kanamori M, Tabuchi Y, Ogawa R, et al. (2010) Ionizing radiation enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulations of death receptor 4 (DR4) and death receptor 5 (DR5) in human osteosarcoma cells. J Orthop Res 28: 739-745.
17. Zhou Y, Song X, Jia R, Wang H, Dai L, et al. (2010) Radiation-inducible human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy: a novel treatment for radioresistant uveal melanoma. Pigment Cell Melanoma Res 23: 661-674.
18. Chatterjee S, Malhotra R, Varghese F, Bukhari AB, Patil A, et al. (2013) Quantitative immunohistochemical analysis reveals association between sodium iodide symporter and estrogen receptor expression in breast cancer. PLoS One 8: e54055.
19. Ryan J, Curran CE, Hennessy E, Newell J, Morris JC, et al. (2011) The sodium iodide symporter (NIS) and potential regulators in normal, benign and malignant human breast tissue. PLoS One 6: e16023.
20. Upadhyay G, Singh R, Agarwal G, Mishra SK, Pal L, et al. (2003) Functional expression of sodium iodide symporter (NIS) in human breast cancer tissue. Breast Cancer Res Treat 77: 157-165.
21. G EBCTC, (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717.
22. Smyth MJ, Godfrey DI, Trapani JA, (2001) A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2: 293-299.
23. Rosenberg SA, Yang JC, Sherry RM, Hwu P, Topalian SL, et al. (2003) Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther 14: 709-714.
24. Fogler WE, Volker K, McCormick KL, Watanabe M, Ortaldo JR, et al. (1996) NK cell infiltration into lung, liver, and subcutaneous B16 melanoma is mediated by VCAM-1/VLA-4 interaction. J Immunol 156: 4707-4714.
25. Gong JH, Maki G, Klingemann HG, (1994) Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8: 652-658.
26. Tonn T, Becker S, Esser R, Schwabe D, Seifried E, (2001) Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res 10: 535-544.
27. Tam YK, Maki G, Miyagawa B, Hennemann B, Tonn T, et al. (1999) Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum Gene Ther 10: 1359-1373.
28. Nagashima S, Mailliard R, Kashii Y, Reichert TE, Herberman RB, et al. (1998) Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo. Blood 91: 3850-3861.
29. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, et al. (2001) Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 19: 197-223.
30. Lanier LL, (2008) Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 9: 495-502.
31. Moretta L, Moretta A, (2004) Killer immunoglobulin-like receptors. Curr Opin Immunol 16: 626-633.
32. Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, et al. (1998) Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med 188: 2375-2380.
33. Xu X, Rao GS, Groh V, Spies T, Gattuso P, et al. (2011) Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression. BMC Cancer 11: 194.
34. Boelaert K, Franklyn JA, (2003) Sodium iodide symporter: a novel strategy to target breast, prostate, and other cancers? Lancet 361: 796-797.
35. Kogai T, Schultz JJ, Johnson LS, Huang M, Brent GA, (2000) Retinoic acid induces sodium/iodide symporter gene expression and radioiodide uptake in the MCF-7 breast cancer cell line. Proc Natl Acad Sci U S A 97: 8519-8524.
36. Dohan O, De la Vieja A, Carrasco N, (2006) Hydrocortisone and purinergic signaling stimulate sodium/iodide symporter (NIS)-mediated iodide transport in breast cancer cells. Mol Endocrinol 20: 1121-1137.
37. Fortunati N, Catalano MG, Marano F, Mugoni V, Pugliese M, et al. (2010) The pan-DAC inhibitor LBH589 is a multi-functional agent in breast cancer cells: cytotoxic drug and inducer of sodium-iodide symporter (NIS). Breast Cancer Res Treat 124: 667-675.